Fungal Keratitis Treatment Market By Product Type (Natamycin, Voriconazole, Amphotericin B, Fluconazole, Posaconazole, Other Antifungal Treatments); By Application (Filamentous Fungal Keratitis, Yeast Fungal Keratitis, Mixed and Other Fungal Keratitis, Refractory and Severe Fungal Keratitis); By End User (Hospitals, Specialty Eye Clinics and Corneal Centres, Ambulatory Surgical Centres, Retail and Specialty Pharmacies, Compounding Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Fungal Keratitis Treatment Market: South Asian Case Volume, Natamycin Access Gaps, and Surgical Escalation Shape Revenue

The Global Fungal Keratitis Treatment Market was valued at USD 1.21 billion in 2025 and is projected to reach USD 1.86 billion by 2032, growing at a CAGR of 6.3%, according to Strategic Market Research.

 

The market serves a large but fragmented patient population. A systematic global review estimated at least 1.05 million fungal keratitis cases annually, including about 939,895 in Asia and 768,325 in Southern Asia. The estimate rises to nearly 1.48 million when infections missed by culture or microscopy are included. Between 8% and 11% of affected eyes were estimated to require removal, making medicine availability, specialist referral, and treatment continuity commercially important across pharmaceutical and hospital-care channels.

 

Revenue comes from commercially supplied natamycin, compounded ophthalmic antifungals, systemic therapy used in selected severe cases, hospital pharmacy services, and corneal surgery after medical failure. Branded products depend on approval and reimbursement, compounded medicines on specialist pharmacy capacity, and public-hospital sales on tender access. Severe cases transfer a larger share of spending to corneal specialists, transplant centres, and long-term follow-up.

 

South Asia Carries the Largest Treatment Volume

Southern Asia recorded an estimated 73 annual cases per 100,000 people in the global review. High incidence is closely associated with rural exposure and ocular trauma. EyeWiki cites trauma in about 40% of infections, although risk patterns vary by geography and climate. Agricultural work, delayed referral, and limited specialist coverage place much of the regional demand in public hospitals and rural eye-care networks rather than premium private channels.

Large case numbers do not automatically produce high revenue per patient. Affordability constraints, weak diagnostic access, stock shortages, and delayed presentation reduce the proportion of patients receiving timely formal treatment. Hospitals in India and neighbouring countries also purchase through local or state systems, creating smaller and less predictable orders than the regional burden might suggest.

South Asian suppliers compete on affordable pricing, local production, tender qualification, and regional inventory. North American suppliers face lower patient volumes but benefit from insurance reimbursement, specialist prescribing, and higher spending per treatment episode. Manufacturers need separate operating models for volume-led public-health markets and value-led specialty markets.

 

Natamycin Retains the Strongest U.S. Treatment Position

The FDA label lists NATACYN 5% ophthalmic suspension for fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms. First approved in 1978, the product remains the only FDA-approved and commercially available topical ophthalmic antifungal identified by the University of Illinois Chicago Drug Information Group. Topical voriconazole and amphotericin B generally require extemporaneous compounding.

Clinical evidence reinforces natamycin’s commercial position rather than relying only on regulatory status. The 323-patient Mycotic Ulcer Treatment Trial found better three-month visual acuity with topical natamycin than with voriconazole in smear-positive filamentous fungal keratitis. Corneal perforation or therapeutic keratoplasty occurred in 18 natamycin-treated patients versus 34 voriconazole-treated patients, while culture positivity after six days was lower with natamycin. The benefit was particularly strong in Fusarium infections.

Organism-specific prescribing still preserves demand for alternatives. Medscape identifies amphotericin B as the preferred treatment for Candida keratitis and notes activity against several filamentous fungi. Voriconazole, amphotericin B, and other compounded agents remain important when organism profile, disease depth, tolerance, or treatment response limits natamycin use.

Commercial availability gives NATACYN an advantage in ordering, reimbursement, hospital stocking, and emergency access. Compounded alternatives require pharmacy capability and preparation time, which can restrict immediate use in low-volume hospitals.

Treatment duration also supports repeat dispensing. The FDA label generally describes 14 to 21 days of therapy, while severe cases can continue much longer. A Canadian multicentre study reported an average treatment duration of 81 days. Longer episodes increase prescription, pharmacy, monitoring, and specialist-service use, although poor response may shift patients into surgery rather than generate continuing medicine revenue.

 

Medicare Spending Is Rising Faster Than Prescription Volume

CMS recorded 1,506 NATACYN claims, 876 Medicare beneficiaries, and 757 prescribers in 2023. Total drug cost reached approximately USD 766,662. The dataset includes other labelled fungal eye infections, so it cannot be treated as fungal-keratitis-only revenue.

Medicare recorded 923 claims, 575 beneficiaries, and about USD 237,264 in total cost in 2013. By 2023, claims had risen by roughly 63%, beneficiaries by 52%, and total drug cost by 223%. Calculated cost per claim increased from about USD 257 to USD 509.

U.S. value growth has depended more on expenditure per prescription than on rapid patient expansion. Higher spending per claim supports specialty-product economics but increases exposure to payer review and affordability pressure. CMS total drug cost includes plan, beneficiary, and other payments; it does not equal manufacturer revenue or list price. Harrow does not disclose NATACYN revenue separately, preventing a reliable calculation of product market share or realised margin.

A concentrated prescriber base favours specialist account coverage over broad promotion. Hospitals, corneal specialists, and ophthalmic pharmacies can influence much of the reimbursed demand.

 

U.S. Demand Is Concentrated in Rural, Southern, and Older Populations

A CDC-authored claims study identified 692 treatment-linked fungal keratitis cases among commercially insured U.S. patients from 2016 to early 2023. Estimated prevalence was 1.8 per 100,000 enrollees, increasing to 3.6 in rural populations, 2.7 in the South, and 6.6 among people aged 65 or older.

Rural eye-care providers, southern referral centres, corneal specialists, and practices serving older patients form the most relevant U.S. customer groups. The same study found that 62 of 586 continuously enrolled patients, or 10.6%, received a corneal transplant. More than one-third had an eye or orbital injury code, and diagnostic testing was recorded for almost three-quarters.

Dispersed demand creates an inventory problem. Individual pharmacies may see few cases, but prescribers need immediate treatment access when an infection appears. Suppliers must support low-volume accounts across a wide geography without relying on frequent turnover at each location.

 

Surgical Escalation Captures a Large Share of Severe-Case Spending

Treatment failure moves spending from outpatient prescriptions toward prolonged hospital care, corneal procedures, transplantation, and follow-up. EyeWiki summarizes clinical series in which severe visual loss affected 26% to 63% of patients, penetrating keratoplasty was required in 31% to 38%, and evisceration occurred in 15% to 20%. These ranges reflect selected studies and should not be treated as universal current rates, but they demonstrate how referral setting and disease severity can change the economic burden.

Recent regional evidence shows similar pressure on specialist services. A Canadian multicentre study examined 138 microbiologically confirmed cases treated between 2003 and 2022. Fifty-six percent required surgery, 42 patients received corneal transplants, and nine underwent eye-removal procedures. Only eight patients accessed NATACYN, usually through special-access or out-of-country routes.

A 2024 study across nine hospitals in Galicia, Spain, identified 77 fungal keratitis cases, equal to 9.9% of microbial keratitis cases in the study population. Surgical intervention was required in 48.1%, and 62.3% of patients lived in rural areas.

Hospitals, transplant centres, and surgical suppliers capture much of the downstream spending. Drug companies benefit when early access keeps patients in medical treatment, but they receive only part of the total expenditure after surgery becomes necessary. Surgery rates therefore indicate unmet need and hospital resource use rather than direct pharmaceutical revenue.

Canada remains a small but commercially relevant access gap. Emergency inventory, hospital formulary inclusion, specialist importation, and support for tertiary eye centres offer more practical routes than widespread retail placement. Multi-product ophthalmic suppliers can spread distribution and regulatory costs across a broader portfolio, improving the economics of serving low-volume countries.

 

Indian Procurement Rewards Local Supply and Fast Fulfilment

A 2025 Government e-Marketplace tender requested 100 bottles of natamycin eye drops for delivery to Patna and required at least 50% local content for Class I local-supplier qualification. A March 2026 tender from K.C. General Hospital in Bengaluru requested 20 units with a 15-day delivery period.

These orders confirm recurring government-hospital demand but also expose fragmented purchasing, small order sizes, and short delivery requirements. Tender documentation, domestic-content eligibility, stock availability, and price often matter more than brand strength.

WHO inclusion of natamycin eye drops for fungal keratitis in its essential-medicines framework supports national formularies and public purchasing. Essential-medicine status also places pressure on suppliers to maintain affordable pricing and reliable availability.

Local manufacturers and distribution partners are better positioned to serve India’s public market because they can qualify for domestic-preference rules and maintain inventory across multiple state and hospital systems.

 

Harrow Controls the Main U.S. Commercial Asset

Harrow completed the NATACYN new drug application transfer and launched the product within its ophthalmic portfolio in 2023 after acquiring rights linked to several Santen products.

Portfolio ownership allows Harrow to use existing relationships with ophthalmologists, distributors, pharmacies, and eye-care institutions. Limited U.S. case volume would make a large standalone commercial organisation difficult to support, while a broader ophthalmic portfolio spreads sales, regulatory, and distribution costs across several products.

Regulatory ownership, standard commercial supply, and established distribution protect Harrow’s position. Compounded products remain a meaningful alternative, but they do not offer the same combination of approved status and routine availability.

Harrow’s 2024 agreement with Ocumension Therapeutics covers mainland China, Hong Kong, Taiwan, and Macau. Ocumension is responsible for regional regulatory and commercial work, while Harrow is expected to provide long-term supply. The partnership gives Harrow geographic reach without building a direct Chinese sales organisation and gives Ocumension an established antifungal asset for a region carrying a large share of the global case burden.

Greater China revenue will depend on approval timing, hospital inclusion, local pricing, domestic competition, and the number of diagnosed patients entering formal treatment. The agreement establishes a route to market but should not be presented as current regional sales.

 

Pipeline and Outbreak Activity Create Selective New Demand

FDA granted orphan-drug designation in March 2025 to IVIEW Therapeutics’ povidone-iodine candidate for fungal keratitis. IVIEW also registered a Phase II study of IVIEW-1201. The programme could challenge a market centred on an older product, but orphan designation does not equal approval. Trial performance, funding, manufacturing, pricing, reimbursement, and comparison with compounded medicines will determine commercial viability.

A new entrant would also need different pricing strategies across insured specialty markets and high-volume public-health countries. Most patients live outside premium U.S. channels, limiting the value of a U.S.-only commercial model.

Institutional outbreaks can create short purchasing spikes. A CDC report published in February 2026 described three fungal keratitis cases among 11 patients who underwent laser eye surgery at a New York City clinic. All three experienced vision loss, and one required corneal transplantation. The investigation identified infection-control deficiencies, expired ocular medicines, and possible nonsterile-water exposure.

Outbreaks can trigger urgent medicine orders, diagnostic services, specialist treatment, and inventory reviews, but they are too unpredictable to support routine growth assumptions.

 

Supply Continuity Determines Commercial Advantage

Harrow holds the strongest identifiable U.S. position through NATACYN, Ocumension provides a Greater China commercialisation route, and IVIEW represents a development-stage challenger. Compounded antifungals remain important where organism profile, treatment response, or product access limits natamycin use.

High-income markets reward approval, reimbursement support, specialist coverage, and emergency distribution. South Asian markets reward local manufacturing, tender eligibility, affordable pricing, and dependable inventory. Low-volume countries require specialist import and hospital-access systems that can operate without large routine sales.

Disease burden creates recurring need, but suppliers convert that need into revenue only when medicines reach hospitals quickly, remain affordable within public systems, and stay available through prolonged treatment episodes.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.21 Billion
Revenue Forecast in 2032	USD 1.86 Billion
Overall Growth Rate	CAGR of 6.3% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Natamycin, Voriconazole, Amphotericin B, Fluconazole, Posaconazole, Other Antifungal Treatments
By Application	Filamentous Fungal Keratitis, Yeast Fungal Keratitis, Mixed and Other Fungal Keratitis, Refractory and Severe Fungal Keratitis
By End User	Hospitals, Specialty Eye Clinics and Corneal Centres, Ambulatory Surgical Centres, Retail and Specialty Pharmacies, Compounding Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, Mexico, Germany, UK, France, Italy, Spain, China, India, Japan, South Korea, Australia, Brazil, Argentina, Saudi Arabia, UAE, South Africa
Market Drivers	Rising fungal corneal infection burden, higher exposure to agricultural eye trauma, expanding use of topical and systemic antifungal therapies, growing demand for specialty ophthalmology care, and stronger clinical focus on early diagnosis to prevent vision loss
Customization Option	Available upon request